Powered by the California Digital Library University of California overall survival, the secondary endpoint was treatment-related acute hematologic toxicity.
Purpose/Objective(s): To test the hypothesis that intensity modulated radiation therapy (IMRT) reduces acute hematologic and gastrointestinal (GI) toxicity for patients with stage IB-IVA cervical cancer undergoing chemoradiation therapy. Materials/Methods: We enrolled patients age > 18 with stage IB-IVA cervical carcinoma on a single-arm phase II trial at 6 centers. All patients received 5-6 weekly cycles of cisplatin (40 mg/m 2 ) concurrently with once daily Gy in 25-28 fractions to the pelvis; gross nodes received up to 59.4 Gy simultaneously), followed by intracavitary brachytherapy as indicated. All centers underwent IMRT credentialing and centralized quality assurance review. Intensity modulated RT plans were designed to minimize radiation dose to the pelvic bone marrow, bowel, bladder, and rectum, while maintaining target coverage. The primary endpoint was the occurrence of either acute grade 3 neutropenia or clinically significant GI toxicity (grade 2 diarrhea requiring intravenous fluids and/or combination opiate/anticholinergic antidiarrheal medication) within 30 days of completing chemoradiation therapy. A pre-planned subgroup analysis was designed to test the hypothesis that PET imageguided bone marrow-sparing IMRT (IG-BMS-IMRT) lowers the risk of acute neutropenia. Toxicity grading was according to NCI CTCAE v4. The trial is registered (NCT01554397). Results: From October 2011 to April 2015, we considered 91 patients, with 8 screen failures and 83 eligible for analysis (86% were FIGO stage IIB-IVA). Median follow-up was 16 months. The incidence of any primary event was 26.5% (95% CI, 18.2-36.9%), significantly lower than the 40% incidence hypothesized a priori from historical data (2-sided t-test P Z 0.007). The incidences of grade 3 neutropenia and clinically significant GI toxicity were 19.3% (95% CI, 12.2-29.1%) and 12.1% (95% CI, 6.7-20.8%), respectively. The incidences of any grade 3 hematologic and grade 2 GI toxicity were 38.6% (95% CI, 28.8-49.3%) and 42.2% (95% CI, 32.1-52.9%), respectively. Compared to patients treated without IG-BMS-IMRT (N Z 48), patients treated with IG-BMS-IMRT (N Z 35) had significantly lower grade 3 neutropenia (8.6% vs. 27.1%, 2-sided chisquare P Z 0.035), and non-significantly lower grade 3 leukopenia (25.7% vs. 41.7%, P Z 0.13) and any grade 3 hematologic toxicity (31.4% vs. 43.8%, P Z 0.26). The 18-month disease-free survival and overall survival were 86.6% (95% CI, 78.1-95.9%) and 98.5% (95% CI, 95.5-100%), respectively. The 18-month cumulative incidences of locoregional failure, distant metastasis, and grade 3 late toxicity were 7.2% (95% CI, 3.6-10.8%), 5.0% (95% CI, 2.1-7.8%), and 8.9% (95% CI, 5.0-12.9%), respectively. Conclusion: Intensity modulated RT reduces acute toxicity compared to standard treatment, with promising outcomes in the international population; IG-BMS-IMRT reduces the risk of acute neutropenia. A phase III trial of IG-BMS-IMRT versus standard of care is warranted. physicians experienced in IMRT for the definitive treatment of cervical cancer in preparation for a collaborative NRG clinical trial. Materials/Methods: A consensus working group that had participated in prior CTV definition was convened to contour on two treatment planning CT scans. Observers were blinded to the corresponding MRI scans. One case was an early cervical cancer and the other a loco-regionally advanced case. Clinical vignettes for the two cases were distributed and each participant was asked to draw CTV contours which included a CTV1 contour for the uterus/cervix and a CTV 2 contour for the vagina/parametria. Participants contoured on CT images of the pelvis using their own treatment planning software. Nodal CTV contours have been well described and were not included in this study. The CTV contours were then analyzed for consistency and clarity of target delineation using an expectation-maximization algorithm for simultaneous truth and performance level estimation (STAPLE, CERR), with Kappa statistics as a measure of agreement between observers. Results: Contoured datasets were merged and analyzed for agreement. CTV1 contours showed almost perfect agreement (Kappa > 0.8), while CTV2 showed moderate agreement (0.4 < Kappa < 0.6) among observers (see Table 1 ).
Conclusion: Agreement among the experienced gynecologic radiation oncologists was excellent for CTV delineation in two representative intact cervical cancer cases. Consensus demonstrated near perfect agreement for the uterus and cervix and moderate agreement for the vagina and parametria. The variability seen in vaginal contours was primarily due to the vaginal length included in the CTV. The value of this data, building on previously published guidelines for IMRT in the post-operative setting and MRI guidance in the intact setting, provides clinically valuable information to promote safety and quality among radiation oncologists treating cervical carcinoma. Furthermore, this atlas will be used for future trials utilizing IMRT for the definitive management of intact cervical cancer. University of California San Diego, La Jolla, CA Purpose/Objective(s): To determine the maximum tolerated dose (MTD) of gemcitabine (GEM) with concurrent weekly cisplatin (CIS) and bone marrow-sparing (BMS) IMRT in women with Stage IB-IVA cervical cancer. Materials/Methods: Twenty-five women were enrolled in a phase I trial with Gy in 25-28 fractions), CIS (40 mg/m 2 weekly) and escalating doses of GEM (50-125 mg/m 2 weekly) followed by HDR brachytherapy (25-30 Gy in 4-5 fractions) as indicated. No adjuvant chemotherapy was given. Cohorts 1 (50 mg/m 2 ; n Z 6), 2 (75 mg/m 2 ; n Z 5), 3 (100 mg/m 2 ; n Z 3), and 4 (125 mg/m 2 ; n Z 3) received CIS immediately followed by GEM, while cohort 5 (125 mg/m 2 ; n Z 5) received GEM followed by CIS. Cohort 1E (n Z 3) received extended field BMS-IMRT (EFRT) with concurrent CIS followed by 50 mg/m 2 GEM weekly. Primary IMRT sparing objectives were bone marrow (BM) (V 10Gy < 90%, V 20Gy < 75%) and bowel (V 45Gy <200 cc). Dose-limiting toxicity (DLT) was defined as grade 4 neutropenia lasting >7 days, neutropenic fever, grade 4 thrombocytopenia, symptomatic grade 3 thrombocytopenia, grade 3 or 4 non-hematologic toxicity (HT), or any treatment related morbidity causing a delay of therapy for > 2 weeks, consistent with a prior GOG study (Rose et al., PMID: 17688925) . Results: Mean BM V 10Gy , V 20Gy , and mean dose were 82.6%, 63.4%, and 26.3 Gy, respectively. Mean bowel V 45Gy and mean dose were 180.5 cc and 26.5 Gy, respectively. DLTs occurred in cohorts 1 and 2 due to protracted nausea/vomiting, in cohort 5 due to grade 4 thrombocytopenia, and cohort 1E due to grade 3 infusion reaction. Acute grade 3 HT occurred in one patient within cohort 1, four patients within cohort 2, two patients each in cohorts 3 and 4, five patients in cohort 5, and three patients in cohort 1E. Acute grade 3 gastrointestinal (GI) toxicity occurred in one patient in cohort 1 and two patients each in cohorts 2 and 3. No patients treated with 125 mg/m 2 developed grade 3 acute GI toxicity. Overall, 18 of 25 patients developed grade 3 toxicity and 3 of 25 patients developed grade 4 toxicity. Six patients developed late grade 2 toxicity: radiation proctitis (n Z 4), vesicovaginal fistula (n Z 1), ureteral stricture (n Z 1), and cystitis (n Z 1). Another patient had a small bowel obstruction attributed to disease progression. With median follow-up of 16 months for patients without para-aortic disease, 1-year (2-year) overall survival was 100% (87.5%) and DFS was 93.3% (86.2%); one patient had LRF and two patients had distant metastasis. Conclusion: With IMRT, concurrent CIS (40 mg/m 2 ) and GEM (125 mg/m 2
